US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Camurus’ Nomination Committee appointed for the Annual General Meeting 2025

Lund, Sweden — 12 November 2024 — Camurus today announced that the Nomination Committee for the Annual General Meeting (AGM), 2025 consists of the following persons, who together represent about 43 percent of the total number of shares and votes in Camurus based on the last known shareholder information: · Per Sandberg, appointed by Sandberg Development AB, · Arne Lööw, appointed by Fjärde AP-fonden, · Oscar Bergman, appointed by Swedbank Robur Fonder, and · Per Olof Wallström, Chairman of the Board of Camurus The Nomination Committee’s proposals will be presented in the

Camurus to present at Jefferies London Healtcare Conference

Lund, Sweden — 11 November 2024 — Camurus (NASDAQ STO: CAMX) announces that Fredrik Tiberg, President and CEO, is presenting at the Jefferies Healthcare Conference in London on 20 November at 1.30 pm local time (GMT), giving an update on the company’s recent development and progress. A webcast of the presentation can be accessed via:https://wsw.com/webcast/jeff315/camx.st/2236248 For more informationFredrik Joabsson, Chief Business Development OfficerTel. +46 (0)70 776 17 37ir@camurus.com (mir@camurus.com) About CamurusCamurus is a Swedish, science-led biopharmaceutical

Camurus’ Interim Report Third Quarter 2024

“Solid third quarter and raised full-year outlook” Summary third quarter 2024 July - September · Total revenues amounted to SEK 480 (384) million. Excluding one-time revenues[1] of SEK 36 million in Q3 2023, company growth was 38% (41% at CER[2]). · Product sales of Buvidal[®] were SEK 421 (346) million, an increase of 22% (24% at CER[2]) and 5% (6% at CER[2]) compared to previous quarter · Brixadi[®] royalties were SEK 58 (1) million, an increase of 30% (39% at CER[2]) compared to previous quarter · Operating result was SEK 142 (104) million · Profit before tax was

Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly

· The FDA issues a Complete Response Letter for CAM2029 pending FDA’s assessment of responses from a third-party manufacturer to observations from a recently completed cGMP inspection · Camurus will work with the FDA and the manufacturer to resolve any potential outstanding observations  Lund, Sweden — 22 October 2024 — Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with

Change in number of shares and votes in Camurus

Lund, Sweden — 30 September 2024 — During September 2024, a total of 171,850 employee stock options in Camurus’ employee stock options program ESOP 2021/2024 have been exercised for subscription of the corresponding number of shares. As a result of the exercises made under ESOP 2021/2024, the number of shares and votes has increased by 171,850. Prior to the exercise, the total number of shares in Camurus amounted to 58,636,918 corresponding to 58,636,918 votes. As of 30 September 2024, the total number of shares in Camurus amounts to 58,808,768, corresponding to 58,808,768 votes.

EMA positive opinion for orphan drug designation to Camurus’ octreotide SC depot for the treatment of polycystic liver disease

Lund, Sweden — 20 September 2024 — Camurus (NASDAQ STO: CAMX) today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has adopted a positive opinion for orphan drug designation (ODD) to the company’s investigational medicinal product, octreotide subcutaneous (SC) depot (CAM2029), for the treatment of autosomal dominant polycystic liver disease (PLD). The European Commission is now assessing the opinion and is expected to grant the designation within 30 days. PLD is a rare, genetic, and chronic disorder characterized by progressive

Exercise in Camurus’ employee stock options program 2021/2024

Lund, Sweden — 19 September 2024 — During September 2024, a total of 142,300 options in Camurus AB’s employee stock options program ESOP 2021/2024 have been exercised for the corresponding number of shares, at an exercise price of SEK 263.50 per share. Through the exercise of the employee stock options, Camurus receives a total of SEK 37.5 million. A number of employees of Camurus, including the company’s CEO, have participated in two forms of cashless exercise, where shares have been sold either in such number that was required to finance the subscription of new shares and taxes related

Camurus’ Interim Report Second Quarter 2024

“High sales growth and strong financial performance in the second quarter” Summary second quarter 2024 April - June · Total revenues amounted to SEK 445 (674) million. Excluding a one-time revenue of SEK 369 million in Q2 2023[1], company growth was 46% (41% at CER[2]) · Product sales of Buvidal[®] were SEK 400 (305) million, an increase of 31% (28% at CER[2]) and 10% (6% at CER[2]) compared to previous quarter · Brixadi[®] royalties were SEK 45 (-) million, an increase of 73% (75% at CER[2]) compared to previous quarter · Operating result was SEK 83 (376) million ·

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

· Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) · Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline · Continuous improvement of acromegaly symptom and quality of life scores vs baseline · Study results reinforce previously reported interim results from ACROINNOVA 2[1] Lund, Sweden, 15 July 2024 — Camurus (NASDAQ STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company’s once-monthly octreotide

Change in number of shares and votes in Camurus

Lund, Sweden — 28 June 2024 — During June 2024, 675,300 employee stock options in Camurus’ employee stock options program ESOP 2021/2024 have been exercised for subscription of the corresponding number of shares. In addition, in order to cover the costs for social security charges related to the program, 98,000 subscription warrants have been sold to Carnegie Investment Bank AB (publ), which has subsequently exercised all 98,000 subscription warrants for subscription of the corresponding number of shares. To ensure that the company can fulfill its commitments under the long-term

New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl

Lund, Sweden — 25 June 2024 — Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 study[1] comparing weekly and monthly subcutaneous (SC) buprenorphine injections (Buvidal[®]/Brixadi[®]) to daily sublingual buprenorphine/naloxone (SL-BPN/NX). The data presented suggests the effectiveness in individuals with opioid dependence who use fentanyl, consistent with the results from the Phase 3 study. “These findings are consistent with the Phase 3 data showing the effectiveness of extended-

Exercise of Camurus’ employee stock options program 2021/2024

Lund, Sweden — 12 June 2024 — As of 12 June 2024, a total of 673,200 options in Camurus AB’s employee stock options program (ESOP) 2021/2024 have been exercised for the corresponding number of shares, at an exercise price of SEK 263.50 per share. Through the exercise of the employee stock options, Camurus receives a total of SEK 177,388,200. A number of employees and senior executives of Camurus have participated in two forms of cashless exercise, where shares have been sold either in such number that was required to finance the subscription of new shares and taxes related to the ESOP

Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2024/2027

Lund, Sweden — 30 May 2024 — The Annual General Meeting of Camurus on 8 May 2024, resolved – for the purpose of ensuring that the company can fulfill its commitments under the long-term incentive program for employees of the Camurus group resolved by the Annual General Meeting (Performance Share Plan 2024/2027) – on a directed share issue of no more than 240,000 redeemable and convertible series C shares. Carnegie Investment Bank AB (publ) has subscribed for all 240,000 series C shares. The subscription price amounted to SEK 0.025 per share, which corresponds to the quota value of the

Camurus to present at Jefferies 2024 Healthcare Conference New York

Lund, Sweden — 28 May 2024 — Camurus (NASDAQ STO: CAMX) announces that Fredrik Tiberg, President and CEO, is presenting at the Jefferies 2024 Healthcare Conference in New York on 5 June at 1 pm local time (ET), giving an update on the company’s recent development and progress. A webcast of the presentation can be accessed via:https://wsw.com/webcast/jeff302/camx.st/2229984 For more informationFredrik Joabsson, Chief Business Development OfficerTel. +46 (0)70 776 17 37ir@camurus.com (mir@camurus.com) About CamurusCamurus is a Swedish, science-led biopharmaceutical company

Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly

Lund, Sweden — 23 May 2024 — Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency (EMA) has accepted for review the company’s Market Authorisation Application (MAA) for octreotide subcutaneous (SC) depot (CAM2029) for the treatment of patients with acromegaly. The acceptance follows the MAA submission done end of April 2024 and marks the beginning of the formal review procedure. CAM2029 is a novel, octreotide subcutaneous depot designed for convenient, once-monthly self-administration by patients and enhanced octreotide plasma exposure with the potential for

Resolutions at the annual general meeting 2024 in Camurus

Lund, Sweden — 8 May 2024 — Camurus AB’s (CAMX) annual general meeting 2024 was held today, Wednesday 8 May, at Elite Hotel Ideon in Lund. The annual general meeting adopted the presented income statements and balance sheets as well as the remuneration report prepared by the Board and granted discharge of liability to Board members and the CEO. In addition, the following main resolutions were passed. Election of Board members and auditorPer Olof Wallström, Hege Hellstrøm, Jakob Lindberg, Stefan Persson, Erika Söderberg Johnsson and Fredrik Tiberg, were re-elected as Board members.

Camurus’ Interim Report January-March 2024

“Increased profitability and strong operational performance” Summary first quarter 2024 January - March · Total revenues amounted to SEK 390 (284) million, an increase of 37% (38% at CER[1]) · Product sales of Buvidal[®] were SEK 364 (282) million, an increase of 29% (30% at CER[1]), and 0% (3% at CER[1]) compared to previous quarter · Brixadi[®] US royalties increased from SEK 8 to 26 million, an increase of 212% (193% at CER[1]) · Operating result was SEK 79 (74) million, an increase of 7% · Profit before tax was SEK 97 (77) million, an increase of 26% · Directed

Notice of annual general meeting 2024 in Camurus (publ)

The shareholders of Camurus AB (publ), Reg. No 556667-9105, are hereby invited to the Annual General Meeting (“AGM”) on 8 May 2024 at 17.00 CEST at Elite Hotel Ideon, Scheelevägen 27, Ideon Science Park, 223 63 Lund, Sweden. Registration for the AGM begins at 16.30 CEST. The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the AGM also by postal voting in accordance with the regulations in Camurus’ Articles of Association. Right to participate and notification A) Participation in the meeting room A person who wishes to attend the

Camurus Annual Report for 2023

Lund, Sweden — 28 March 2024 — Camurus (CAMX) today announces that the Annual Report for 2023 now is available at the company’s website: www.camurus.com, and as an attachment to this press release. The Swedish version of the Annual Report is also available on the website in European Single Electronic Format (ESEF). The Annual Report also includes Camurus’ sustainability report. Fredrik Tiberg, President and CEO:“Camurus performed strongly during the year towards our vision of becoming a global, long-term sustainable, specialty pharmaceutical company focused on the development of

Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly

Prescription Drug User Fee Act date (PDUFA) set to 21 October 2024 Lund, Sweden — 5 March 2024 — Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for Oclaiz[TM] (CAM2029) for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of 21 October 2024. CAM2029 is a novel, octreotide subcutaneous depot designed for convenient, once-monthly self-administration, enhanced octreotide plasma exposure, and robust disease

Camurus’ Full Year Report 2023

“An excellent fourth quarter with significant growth and pipeline progress” Fourth quarter and full year summary October - December · Total revenues amounted to SEK 375 (268) million, an increase of 40% (36% at CER[1]), whereof product sales were SEK 366 (267) million, an increase of 37% (33% at CER[1]) · Compared to the previous quarter, product sales increased 6% (7% at CER[1]) · Operating result was SEK -29 (19) million, a decrease of SEK 47 million, including SEK 51 million social security costs accrual in the quarter relating to employee long term incentive programs,

Camurus appoints Behshad Sheldon as President of Camurus Inc.

Lund, Sweden — 13 February 2024 — Camurus AB (NASDAQ STO: CAMX) today announced the appointment of Behshad Sheldon as President of Camurus Inc. and member of the company’s executive management team, starting 1 April 2024. Behshad has been a member of Camurus’ Board of Directors since 2018, contributing to Camurus’ development as a successful and profitable, commercial-stage pharmaceutical company. Behshad brings more than 25 years of experience from leading positions within the international pharmaceutical industry, including as President & CEO of Braeburn Pharmaceuticals up to 2017, and

Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease

Lund, Sweden — 8 February 2024 — Camurus (NASDAQ STO: CAMX) today announces completed enrollment in the randomized, double-blind, placebo-controlled, multicenter Phase 2/3 study, POSITANO, evaluating the efficacy and safety of the company’s octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver disease (PLD). PLD is a rare, genetic, and chronic disorder characterized by progressive growth of cysts in the liver, which can cause severe symptoms and result in impaired quality of life for patients. An estimated 37,000 patients in the US and EU are today living

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media